Printer Friendly

DIACRIN, INC. NAMES E. MICHAEL EGAN AS SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT

 CHARLESTOWN, Mass., June 22 /PRNewswire/ -- Diacrin, Inc. today announced that it has named E. Michael Egan to senior vice president of corporate development. Egan joins Diacrin from Repligen Corporation where he was vice president of business development.
 "We are very pleased to have Michael join us during this period of rapid growth," commented Thomas H. Fraser, Ph.D., president and CEO of Diacrin. "With his extensive, broad-based business development and marketing experience, he will be instrumental in accelerating the commercialization of our current transplantable cell products in development as well as expanding Diacrin's product portfolio." Dr. Fraser noted that Phase I trials are underway at Massachusetts General Hospital to evaluate Diacrin's myoblast transplantation program in patients with Becker's muscular dystrophy. In its islet transplantation program, Diacrin is conducting studies in a non-human primate model of diabetes to support the initiation of clinical trials.
 During his tenure at Repligen, Egan established important strategic alliances for the company with a number of major international pharmaceutical companies. He was responsible for the development of marketing and business strategies, negotiating license and development contracts, and identifying new development and product opportunities. He was a member of the board of directors of Repligen Clinical Partners, L.P., and the secretary/treasurer of Repligen Sandoz Research Corporation. Egan's previous positions at Repligen include director of business development and manager of business development.
 Prior to joining Repligen in 1983, Egan was a laboratory supervisor at Dana-Farber Cancer Institute, Division of Medicine. He received a B.S. in biology from Boston College in 1976, and a Certificate of Special Studies in administration and management from Harvard University in 1986.
 Diacrin, Inc. is developing proprietary cell transplantation therapies to treat major human diseases, including diabetes, muscular dystrophy, hypercholesteremia, Huntington's and Parkinson's disease. Diacrin was founded in 1989 and is based in Charlestown, Mass.
 -0- 6/22/93
 /CONTACT: Thomas H. Fraser, Ph.D., president and CEO, Diacrin, Inc., 617-242-9100; Lynne H. Brum, Feinstein Partners Inc., 617-577-8110, for Diacrin, Inc./


CO: Diacrin, Inc. ST: Massachusetts IN: MTC SU: PER

CM -- NE001 -- 4406 06/22/93 09:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 22, 1993
Words:348
Previous Article:NORTECH SYSTEMS ANNOUNCES PROMOTION
Next Article:BRADLEES, INC. REPORTS FIRST QUARTER RESULTS
Topics:


Related Articles
CENTEX NAMES NEW VICE PRESIDENT-FINANCE
ARISTECH CHEMICAL CORPORATION ANNOUNCES NEW SENIOR MANAGEMENT TEAM
REGEN NAMES NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER
DIACRIN ANNOUNCES FIRST QUARTER RESULTS
TransMolecular Appoints E. Michael Egan as Chief Executive Officer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters